• 1
    Parkin DM,Bray F,Ferlay J,Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74108.
  • 2
    Guppy AE,Nathan PD,Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol. 2005; 17: 399411.
  • 3
    Ozols RF. Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer. Cancer Invest. 2004; 22(suppl 2): 1120.
  • 4
    Thigpen T. First-line therapy for ovarian carcinoma: what's next? Cancer Invest. 2004; 22(suppl 2): 2128.
  • 5
    Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs. 2001; 61: 10571065.
  • 6
    Dedrick RL,Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997; 89: 480487.
  • 7
    DerSimonian R,Laird A. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177188.
  • 8
    Armstrong DK,Bundy B,Wenzel L, et al. Gynecologic Oncology Group.Intraperitoneal cisplatin and paclitaxel in ovarian cancer.N Engl J Med.2006;354:3443.
  • 9
    Markman M,Bundy BN,Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001; 19: 10011007.
  • 10
    Alberts DS,Liu PY,Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996; 335: 19501955.
  • 11
    Yen MS,Juang CM,Lai CR,Chao GC,Ng HT,Yuan CC. Intraperitoneal cisplatin-based chemotherapy vs intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynecol Obstet. 2001; 72: 5560.
  • 12
    Gadducci A,Carnino F,Chiara S, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol. 2000; 76: 157162.
  • 13
    Polyzos A,Tsavaris N,Kosmas C, et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology. 1999; 56: 291296.
  • 14
    Kirmani S,Braly PS,McClay EF, et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol. 1994; 54: 338344.
  • 15
    Walker JL,Armstrong DK,Huang HQ, et al. Intraperitoneal catheter outcomes in a Phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006; 100: 2732.
  • 16
    Markman M,Reichman B,Hakes T, et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol Oncol. 1993; 50: 100104.
  • 17
    Fujiwara K,Suzuki S,Ishikawa H,Oda T,Aotani E,Kohno I. Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube. Int J Gynecol Cancer. 2005; 15: 426431.
  • 18
    Miyagi Y,Fujiwara K,Kigawa J, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs intravenous infusion of carboplatin—a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol. 2005; 99: 591596.
  • 19
    Fujiwara K,Sakuragi N,Suzuki S, et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol. 2003; 90: 637643. Erratum inGynecol Oncol.2003;91:662.
  • 20
    Alberts DS,Markman M,Armstrong D,Rothenberg ML,Muggia F,Howell SB. Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol. 2002; 20: 39443946.
  • 21
    Markman M,Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol. 2006; 24: 988994.
  • 22
    National Cancer Institute. NCI Issues clinical announcement for preferred method of treatment for advanced ovarian cancer. Available at: Accessed November 6, 2006.
  • 23
    Society of Gynecologic Oncologists. Statement on use of intraperitoneal (IP) chemotherapy for ovarian cancer. Available at: Accessed November 6, 2006.
  • 24
    The Society of Gynecologic Oncologists of Canada. Intraperitoneal chemotherapy for ovarian cancer: a complex strategy but what an exciting avenue! Available at: Accessed November 6, 2006.